5 July 2024
Fee Reduction for Non-Commercial Clinical Trials
Swissmedic is reducing fees for non-commercially funded clinical trial applications by 80%, effective 1 July 2024. This supports Switzerland's status as a research hub without changing the quality and method of assessment. The reduction benefits independent researchers, including universities and non-commercial research bodies. Researchers can apply for the fee reduction using the relevant form (see here).
For more information, see here.
More News
-
-
Swissmedic: New strategic Approach to minimizing Animal Testing in the Development of Medicinal Products
-
European Medicines Agency: New oral GLP-1 Medicine for Weight Management and Type 2 Diabetes
-
Swissmedic: The new Pharmacopoea Helvetica 13
-
FOPH: Capital Income of Health Insurers for Premium Reduction – current voluntary System deemed sufficient
-
Decision C-6534/2024 of 13 October 2026
-
Swissmedic: Haemovigilance Annual Report 2025
-
Swissmedic: GMP Compliance by foreign Manufacturers - Simplifications for Industry and Clarification of unresolved Issues
-
European Medicines Agency: Clinical Trial Applications Advice Pilot becomes permanent
-
European Medicines Agency: Highlights of the September 2026 Management Board meeting